OPTIPHARM.CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,670 KRW | -0.45% |
|
+3.73% | -5.12% |
| 2023 | Optipharm.CO.,LTD Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| 2022 | Optipharm.CO.,LTD(KOSDAQ:A153710) dropped from S&P Global BMI Index | CI |
| Sales 2022 | 16.01B 11.64M | Sales 2023 | 17.37B 12.63M | Capitalization | 103B 74.98M |
|---|---|---|---|---|---|
| Net income 2022 | -2.04B -1.49M | Net income 2023 | -2.44B -1.77M | EV / Sales 2022 | 5.87 x |
| Net cash position 2022 | 8.9B 6.47M | Net cash position 2023 | 5.6B 4.07M | EV / Sales 2023 | 5.61 x |
| P/E ratio 2022 |
-50.2
x | P/E ratio 2023 |
-42.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 58.98% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.45% | ||
| 1 week | +3.73% | ||
| Current month | -5.52% | ||
| 1 month | -3.33% | ||
| 3 months | -3.75% | ||
| 6 months | -7.36% | ||
| Current year | -5.12% |
1 week
6 360.00
6 790.00
1 month
6 350.007 230.00
Current year
6 110.007 230.00
1 year
6 110.009 680.00
3 years
6 110.0017 950.00
5 years
4 700.0031 150.00
10 years
4 700.0031 150.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hyun-Il Kim
CEO | Chief Executive Officer | 52 | - |
Ki-Myung Choi
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Beom-Gu Han
BRD | Director/Board Member | 55 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hyun-Il Kim
CEO | Chief Executive Officer | 52 | - |
Ki-Myung Choi
CTO | Chief Tech/Sci/R&D Officer | 52 | - |
Young-Ho Kim
BRD | Director/Board Member | 47 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6,670 | -0.45% | 7,497 |
| 24-04-25 | 6,700 | +0.90% | 8,879 |
| 24-04-24 | 6,640 | +2.47% | 10,105 |
| 24-04-23 | 6,480 | +0.78% | 10,844 |
| 24-04-22 | 6,430 | 0.00% | 6,987 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Optipharm.CO.,LTD is a Korea-based company mainly engaged in the production and sale of veterinary drugs. The Company operates its business through two segments. The Sale Business segment is involved in the provision of livestock disease appraisal services, animal drug distribution, and the manufacturing and sale of feed additives. The New Business segment is engaged in research and development of heterologous organisms, virus like particle (VLP) vaccines, and human diagnostic kits. Heterogeneous organ products include heterologous skin, xenogeneic islets and xenogeneic corneal products, among others. VLP vaccines include VLP based animal combined vaccines and human papillomavirus (HPV) vaccines for the human body, among others. Human body diagnostic kits include human breast cancer and cervical cancer diagnostic reagents, among others. The Company distributes its products within the domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -5.12% | 71.56M | |
| -19.73% | 70.08B | |
| -11.01% | 6.43B | |
| +15.88% | 3.52B | |
| -2.92% | 3.11B | |
| -0.68% | 1.38B | |
| -17.27% | 1.37B | |
| -2.73% | 1.24B | |
| -14.67% | 1.13B | |
| -5.37% | 1.02B |
- Stock Market
- Equities
- A153710 Stock
